Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine

Matthew J. Byerly, Paul A. Nakonezny, Brianne Magouirk Bettcher, Thomas Carmody, Robert Fisher, A. John Rush

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.

Original languageEnglish (US)
Pages (from-to)244-250
Number of pages7
JournalSchizophrenia Research
Volume86
Issue number1-3
DOIs
StatePublished - Sep 2006

Fingerprint

olanzapine
Risperidone
Psychotic Disorders
Antipsychotic Agents
Schizophrenia
Outpatients
Therapeutics
Quetiapine Fumarate

Keywords

  • Antipsychotics
  • Schizophrenia
  • Sexual dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder : An empirical evaluation of olanzapine, risperidone, and quetiapine. / Byerly, Matthew J.; Nakonezny, Paul A.; Bettcher, Brianne Magouirk; Carmody, Thomas; Fisher, Robert; Rush, A. John.

In: Schizophrenia Research, Vol. 86, No. 1-3, 09.2006, p. 244-250.

Research output: Contribution to journalArticle

@article{fbc355a365e249c190522b42cf506c88,
title = "Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine",
abstract = "Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.",
keywords = "Antipsychotics, Schizophrenia, Sexual dysfunction",
author = "Byerly, {Matthew J.} and Nakonezny, {Paul A.} and Bettcher, {Brianne Magouirk} and Thomas Carmody and Robert Fisher and Rush, {A. John}",
year = "2006",
month = "9",
doi = "10.1016/j.schres.2006.04.005",
language = "English (US)",
volume = "86",
pages = "244--250",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder

T2 - An empirical evaluation of olanzapine, risperidone, and quetiapine

AU - Byerly, Matthew J.

AU - Nakonezny, Paul A.

AU - Bettcher, Brianne Magouirk

AU - Carmody, Thomas

AU - Fisher, Robert

AU - Rush, A. John

PY - 2006/9

Y1 - 2006/9

N2 - Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.

AB - Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age ≥ 18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n = 57), olanzapine (n = 94), or risperidone (n = 87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M = 16.6 mg/day, SD = 7.4) for olanzapine; 1 to 8 mg/day (M = 3.9 mg/day, SD = 1.6) for risperidone; and 50 to 900 mg/day (M = 376.8 mg/day, SD = 213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p = .04). The adjusted average ASEX total scores were lower in the quetiapine (M = 17.80) than in the risperidone (M = 19.69) or olanzapine (M = 20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p = .04), but no difference between risperidone and quetiapine (p = .17) or olanzapine and risperidone (p = .76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.

KW - Antipsychotics

KW - Schizophrenia

KW - Sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=33747184801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747184801&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2006.04.005

DO - 10.1016/j.schres.2006.04.005

M3 - Article

C2 - 16730951

AN - SCOPUS:33747184801

VL - 86

SP - 244

EP - 250

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -